These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19409634)

  • 1. Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment.
    Phan JH; Moffitt RA; Stokes TH; Liu J; Young AN; Nie S; Wang MD
    Trends Biotechnol; 2009 Jun; 27(6):350-8. PubMed ID: 19409634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression.
    Cooley LS; Rudewicz J; Souleyreau W; Emanuelli A; Alvarez-Arenas A; Clarke K; Falciani F; Dufies M; Lambrechts D; Modave E; Chalopin-Fillot D; Pineau R; Ambrosetti D; Bernhard JC; Ravaud A; Négrier S; Ferrero JM; Pagès G; Benzekry S; Nikolski M; Bikfalvi A
    Mol Cancer; 2021 Oct; 20(1):136. PubMed ID: 34670568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptomics in RCC.
    Syed JS; Brito J; Pooli A; Boutros PC; Shuch B
    Urol Oncol; 2020 Oct; 38(10):742-754. PubMed ID: 32222350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and Future Biomarkers in the Management of Renal Cell Carcinoma.
    Reese S; Calderon L; Khaleel S; Hakimi AA
    Urol Clin North Am; 2023 Feb; 50(1):151-159. PubMed ID: 36424079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renal cell cancer].
    Németh I; Iványi B; Pajor L
    Orv Hetil; 2006 Jul; 147(28):1336-7. PubMed ID: 16999021
    [No Abstract]   [Full Text] [Related]  

  • 6. Nanotechnology for targeted cancer therapy.
    Wang MD; Shin DM; Simons JW; Nie S
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):833-7. PubMed ID: 17555393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise of biomarkers for personalized renal cancer care.
    Devarajan P
    Kidney Int; 2010 May; 77(9):755-7. PubMed ID: 20393489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomics and proteomics in renal cell carcinoma: diagnosis, prognosis, and treatment selection.
    Jones J; Pantuck AJ
    Curr Urol Rep; 2008 Jan; 9(1):9-14. PubMed ID: 18366968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnology in cancer diagnosis: progress, challenges and opportunities.
    Zhang Y; Li M; Gao X; Chen Y; Liu T
    J Hematol Oncol; 2019 Dec; 12(1):137. PubMed ID: 31847897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.
    Osunkoya AO; Yin-Goen Q; Phan JH; Moffitt RA; Stokes TH; Wang MD; Young AN
    Hum Pathol; 2009 Dec; 40(12):1671-8. PubMed ID: 19695674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Management of Advanced Kidney Cancer.
    Graham J; Heng DYC; Brugarolas J; Vaishampayan U
    Am Soc Clin Oncol Educ Book; 2018 May; 38():330-341. PubMed ID: 30231375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research advancement and prospects of nanotechnology in early diagnosis and treatment of cancer].
    Hu DH; Gong P; Ma YF; Cai LT
    Ai Zheng; 2009 Sep; 28(9):1000-3. PubMed ID: 19728922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Personalised medicine in renal cell tumours].
    Junker K; Zeuschner P
    Aktuelle Urol; 2019 Sep; 50(5):513-523. PubMed ID: 31167243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.
    Romero-Laorden N; Doger B; Hernandez M; Hernandez C; Rodriguez-Moreno JF; Garcia-Donas J
    Clin Transl Oncol; 2016 Jan; 18(1):1-8. PubMed ID: 26169213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Biomarkers in Renal Cell Carcinoma.
    Saliby RM; Saad E; Kashima S; Schoenfeld DA; Braun DA
    Am Soc Clin Oncol Educ Book; 2024 Jan; 44(2):e430734. PubMed ID: 38207251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genitourinary imaging: part 2, role of imaging in medical management of advanced renal cell carcinoma.
    Shinagare AB; Krajewski KM; Jagannathan JP; Ramaiya NH
    AJR Am J Roentgenol; 2012 Nov; 199(5):W554-64. PubMed ID: 23096199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.
    Golovastova MO; Korolev DO; Tsoy LV; Varshavsky VA; Xu WH; Vinarov AZ; Zernii EY; Philippov PP; Zamyatnin AA
    Curr Urol Rep; 2017 Jan; 18(1):3. PubMed ID: 28110463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting clinically-driven biomarkers for cancer nanotechnology.
    Phan JH; Young AN; Wang MD
    Conf Proc IEEE Eng Med Biol Soc; 2006; 2006():3317-20. PubMed ID: 17947020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NCCN clinical practice guidelines in oncology: kidney cancer.
    Motzer RJ; Agarwal N; Beard C; Bolger GB; Boston B; Carducci MA; Choueiri TK; Figlin RA; Fishman M; Hancock SL; Hudes GR; Jonasch E; Kessinger A; Kuzel TM; Lange PH; Levine EG; Margolin KA; Michaelson MD; Olencki T; Pili R; Redman BG; Robertson CN; Schwartz LH; Sheinfeld J; Wang J
    J Natl Compr Canc Netw; 2009 Jun; 7(6):618-30. PubMed ID: 19555584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.